Carboprost tromethamine injection sterile solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. Carboprost tromethamine injection should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings
WARNINGS Carboprost tromethamine injection sterile solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. Carboprost tromethamine injection should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities. Carboprost tromethamine injection does not appear to directly affect the fetoplacental unit. Therefore, the possibility does exist that the previable fetus aborted by carboprost tromethamine injection could exhibit transient life signs. Carboprost tromethamine injection is not indicated if the fetus in utero has reached the stage of viability. Carboprost tromethamine injection should not be considered a feticidal agent. Evidence from animal studies has suggested that certain other prostaglandins have some teratogenic potential. Although these studies do not indicate that carboprost tromethamine injection is teratogenic, any pregnancy termination with carboprost tromethamine injection that fails should be completed by some other means. This product contains benzyl alcohol. Benzyl alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants.
ADVERSE REACTIONS The adverse effects of carboprost tromethamine injection sterile solution are generally transient and reversible when therapy ends. The most frequent adverse reactions observed are related to its contractile effect on smooth muscle. In patients studied, approximately two-thirds experienced vomiting and diarrhea, approximately one-third had nausea, one-eighth had a temperature increase greater than 2° F, and one-fourteenth experienced flushing. The pretreatment or concurrent administration of antiemetic and antidiarrheal drugs decreases considerably the very high incidence of gastrointestinal effects common with all prostaglandins used for abortion. Their use should be considered an integral part of the management of patients undergoing abortion with carboprost tromethamine injection. Of those patients experiencing a temperature elevation, approximately one-sixteenth had a clinical diagnosis of endometritis. The remaining temperature elevations returned to normal within several hours after the last injection. Adverse effects observed during the use of carboprost tromethamine injection for abortion and for hemorrhage, not all of which are clearly drug related, in decreasing order of frequency include: Vomiting Diarrhea Nausea Flushing or hot flashes Chills or shivering Coughing Headaches Endometritis Hiccough Dysmenorrhea-like pain Paresthesia Backache Muscular pain Breast tenderness Eye pain Drowsiness Dystonia Asthma Injection site pain Tinnitus Vertigo Vaso-vagal syndrome Dryness of mouth Hyperventilation Respiratory distress Hematemesis Taste alterations Urinary tract infection Septic shock Torticollis Lethargy Hypertension Tachycardia Pulmonary edema Endometritis from IUCD Nervousness Nosebleed Sleep disorders Dyspnea Tightness in chest Wheezing Posterior cervical perforation Weakness Diaphoresis Dizziness Blurred vision Epigastric pain Excessive thirst Twitching eyelids Gagging, retching Dry throat Sensation of choking Thyroid storm Syncope Palpitations Rash Upper respiratory infection Leg cramps Perforated uterus Anxiety Chest pain Retained placental fragment Shortness of breath Fullness of throat Uterine sacculation Faintness, light- headedness Uterine rupture The most common complications when carboprost tromethamine injection was utilized for abortion requiring additional treatment after discharge from the hospital were endometritis, retained placental fragments, and excessive uterine bleeding, occurring in about one in every 50 patients. Post-marketing experience: Hypersensitivity reactions (e.g. Anaphylactic reaction, Anaphylactic shock, Anaphylactoid reaction, Angioedema). To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-800-308-6755 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
adverse reactions table
<table width="100%"><col width="49%"/><col width="49%"/><tbody><tr styleCode="Toprule"><td valign="top"><paragraph>Vomiting</paragraph><paragraph>Diarrhea</paragraph><paragraph>Nausea</paragraph><paragraph>Flushing or hot flashes</paragraph><paragraph>Chills or shivering</paragraph><paragraph>Coughing</paragraph><paragraph>Headaches</paragraph><paragraph>Endometritis</paragraph><paragraph>Hiccough </paragraph><paragraph>Dysmenorrhea-like pain</paragraph><paragraph>Paresthesia</paragraph><paragraph>Backache</paragraph><paragraph>Muscular pain</paragraph><paragraph>Breast tenderness</paragraph><paragraph>Eye pain</paragraph><paragraph>Drowsiness</paragraph><paragraph>Dystonia</paragraph><paragraph>Asthma</paragraph><paragraph>Injection site pain</paragraph><paragraph>Tinnitus</paragraph><paragraph>Vertigo</paragraph><paragraph>Vaso-vagal syndrome</paragraph><paragraph>Dryness of mouth</paragraph><paragraph>Hyperventilation</paragraph><paragraph>Respiratory distress</paragraph><paragraph>Hematemesis</paragraph><paragraph>Taste alterations</paragraph><paragraph>Urinary tract infection</paragraph><paragraph>Septic shock</paragraph><paragraph>Torticollis</paragraph><paragraph>Lethargy</paragraph><paragraph>Hypertension</paragraph><paragraph>Tachycardia</paragraph><paragraph>Pulmonary edema</paragraph><paragraph>Endometritis from IUCD</paragraph></td><td valign="top"><paragraph>Nervousness</paragraph><paragraph>Nosebleed</paragraph><paragraph>Sleep disorders</paragraph><paragraph>Dyspnea</paragraph><paragraph>Tightness in chest</paragraph><paragraph>Wheezing</paragraph><paragraph>Posterior cervical perforation</paragraph><paragraph>Weakness</paragraph><paragraph>Diaphoresis</paragraph><paragraph>Dizziness</paragraph><paragraph>Blurred vision</paragraph><paragraph>Epigastric pain</paragraph><paragraph>Excessive thirst</paragraph><paragraph>Twitching eyelids</paragraph><paragraph>Gagging, retching</paragraph><paragraph>Dry throat</paragraph><paragraph>Sensation of choking</paragraph><paragraph>Thyroid storm</paragraph><paragraph>Syncope</paragraph><paragraph>Palpitations</paragraph><paragraph>Rash</paragraph><paragraph>Upper respiratory infection</paragraph><paragraph>Leg cramps</paragraph><paragraph>Perforated uterus</paragraph><paragraph>Anxiety</paragraph><paragraph>Chest pain</paragraph><paragraph>Retained placental fragment</paragraph><paragraph>Shortness of breath</paragraph><paragraph>Fullness of throat</paragraph><paragraph>Uterine sacculation</paragraph><paragraph>Faintness, light- headedness</paragraph><paragraph>Uterine rupture</paragraph></td></tr></tbody></table>